287 related articles for article (PubMed ID: 19505383)
1. In vitro evaluation of the synergistic activity of neomycin-polymyxin B association against pathogens responsible for otitis externa.
Tempera G; Mangiafico A; Genovese C; Giudice E; Mastrojeni S; Nicolosi D; Ferneri PM
Int J Immunopathol Pharmacol; 2009; 22(2):299-302. PubMed ID: 19505383
[TBL] [Abstract][Full Text] [Related]
2. Declining susceptibility to neomycin and polymyxin B of pathogens recovered in otitis externa clinical trials.
Cantrell HF; Lombardy EE; Duncanson FP; Katz E; Barone JS
South Med J; 2004 May; 97(5):465-71. PubMed ID: 15180022
[TBL] [Abstract][Full Text] [Related]
3. Acute otitis externa: an update.
Schaefer P; Baugh RF
Am Fam Physician; 2012 Dec; 86(11):1055-61. PubMed ID: 23198673
[TBL] [Abstract][Full Text] [Related]
4. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.
Schwartz RH
Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576
[TBL] [Abstract][Full Text] [Related]
5. Differences in bacteriologic treatment failures in acute otitis externa between ciprofloxacin/dexamethasone and neomycin/polymyxin B/hydrocortisone: results of a combined analysis.
Dohar JE; Roland P; Wall GM; McLean C; Stroman DW
Curr Med Res Opin; 2009 Feb; 25(2):287-91. PubMed ID: 19192973
[TBL] [Abstract][Full Text] [Related]
6. Pooled analysis of two clinical trials comparing the clinical outcomes of topical ciprofloxacin/dexamethasone otic suspension and polymyxin B/neomycin/hydrocortisone otic suspension for the treatment of acute otitis externa in adults and children.
Rahman A; Rizwan S; Waycaster C; Wall GM
Clin Ther; 2007 Sep; 29(9):1950-6. PubMed ID: 18035194
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of ciprofloxacin otic solution 0.2% versus polymyxin B-neomycin-hydrocortisone in the treatment of acute diffuse otitis externa*.
Drehobl M; Guerrero JL; Lacarte PR; Goldstein G; Mata FS; Luber S
Curr Med Res Opin; 2008 Dec; 24(12):3531-42. PubMed ID: 19032135
[TBL] [Abstract][Full Text] [Related]
8. The joint in vitro action of polymyxin B and miconazole against pathogens associated with canine otitis externa from three European countries.
Pietschmann S; Meyer M; Voget M; Cieslicki M
Vet Dermatol; 2013 Aug; 24(4):439-45, e96-7. PubMed ID: 23721182
[TBL] [Abstract][Full Text] [Related]
9. Otitis externa: clinical comparison of local ciprofloxacin versus local oxytetracycline, polymyxin B, hydrocortisone combination treatment.
Arnes E; Dibb WL
Curr Med Res Opin; 1993; 13(3):182-6. PubMed ID: 8222746
[TBL] [Abstract][Full Text] [Related]
10. [The species composition and sensitivity of pathogenic microflora responsible for the development of otitis externa diffusa to the components of Polidexa].
Krasnozhen VN; Pokrovskaya EM; Bayazitova LT
Vestn Otorinolaringol; 2018; 83(1):65-67. PubMed ID: 29488502
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa.
Roland PS; Pien FD; Schultz CC; Henry DC; Conroy PJ; Wall GM; Garadi R; Dupre SJ; Potts SL; Hogg LG; Stroman DW;
Curr Med Res Opin; 2004 Aug; 20(8):1175-83. PubMed ID: 15324520
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Antimicrobial Activity Between the Broad Spectrum Bacteriocin Garvicin KS and Nisin, Farnesol and Polymyxin B Against Gram-Positive and Gram-Negative Bacteria.
Chi H; Holo H
Curr Microbiol; 2018 Mar; 75(3):272-277. PubMed ID: 29058043
[TBL] [Abstract][Full Text] [Related]
13. Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia.
Jones RN; Li Q; Kohut B; Biedenbach DJ; Bell J; Turnidge JD
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):63-71. PubMed ID: 16368476
[TBL] [Abstract][Full Text] [Related]
14. Is transmission electron microscopy (TEM) a promising approach for qualitative and quantitative investigations of polymyxin B and miconazole interactions with cellular and subcellular structures of Staphylococcus pseudintermedius, Escherichia coli, Pseudomonas aeruginosa and Malassezia pachydermatis?
Voget M; Lorenz D; Lieber-Tenorio E; Hauck R; Meyer M; Cieslicki M
Vet Microbiol; 2015 Dec; 181(3-4):261-70. PubMed ID: 26527257
[TBL] [Abstract][Full Text] [Related]
15. A single topical agent is clinically equivalent to the combination of topical and oral antibiotic treatment for otitis externa.
Roland PS; Belcher BP; Bettis R; Makabale RL; Conroy PJ; Wall GM; Dupre S; Potts S; Hogg G; Weber K;
Am J Otolaryngol; 2008; 29(4):255-61. PubMed ID: 18598837
[TBL] [Abstract][Full Text] [Related]
16. Formulation of 'idealized' topical antimicrobial mixtures for use with cultured skin grafts.
Holder IA; Boyce ST
J Antimicrob Chemother; 1996 Sep; 38(3):457-63. PubMed ID: 8889720
[TBL] [Abstract][Full Text] [Related]
17. A study of three preparations in the treatment of otitis externa.
Slack RW
J Laryngol Otol; 1987 Jun; 101(6):533-5. PubMed ID: 3036980
[TBL] [Abstract][Full Text] [Related]
18. In vitro interactions of neomycin sulfate, bacitracin, and polymyxin B sulfate.
Booth JH; Benrimoj SI; Nimmo GR
Int J Dermatol; 1994 Jul; 33(7):517-20. PubMed ID: 7928043
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial of a topical preparation of miconazole, polymyxin and prednisolone in the treatment of otitis externa in dogs.
Studdert VP; Hughes KL
Aust Vet J; 1991 Jun; 68(6):193-5. PubMed ID: 1888310
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of monensin against common clinical isolates associated with canine otitis externa.
Chan WY; Hickey EE; Khazandi M; Page SW; Trott DJ; Hill PB
Comp Immunol Microbiol Infect Dis; 2018 Apr; 57():34-38. PubMed ID: 30017076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
